AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8326047 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate checkup with client‐centered counseling
Number of subjects: 42
Study 8326047 — intervention group
Group type: COMPARATOR
Intervention: Delayed checkup (waiting‐list control)
Number of subjects: 42
Study 2878745 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal synthetic LHRH
Number of subjects: 49
Study 2878745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 31875687 — intervention group
Group type: EXPERIMENTAL
Intervention: Two complementary sets of rules governing rehabilitation delivery
Number of subjects: 285
Study 31875687 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation without any specified guidelines
Number of subjects: 285
Study 30861532 — intervention group
Group type: EXPERIMENTAL
Intervention: PGA group (polyglycolic acid sheets and fibrin glue)
Number of subjects: 137
Study 30861532 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 137
Study 28111428 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day) plus Afatinib (40 mg/day)
Number of subjects: 68
Study 28111428 — intervention group
Group type: COMPARATOR
Intervention: Afatinib (40 mg/day)
Number of subjects: 68
Study 25781231 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan Depletion (TD)
Number of subjects: 0
Study 25781231 — intervention group
Group type: EXPERIMENTAL
Intervention: Catecholamine Depletion (CD)
Number of subjects: 0
Study 23967632 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion group
Number of subjects: 123
Study 23967632 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication group
Number of subjects: 123
Study 23967632 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture + medication group
Number of subjects: 123
Study 21524798 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous tactile communication group
Number of subjects: 40
Study 21524798 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuous non-periodic tactile communication group
Number of subjects: 40
Study 21524798 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuous periodic tactile communication group
Number of subjects: 40
Study 21524798 — intervention group
Group type: COMPARATOR
Intervention: Absent communication group
Number of subjects: 40
Study 18981486 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite primary outcome
Number of subjects: 304
Study 18981486 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite secondary outcome
Number of subjects: 304
Study 18981486 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite outcomes
Number of subjects: 304
Study 18981486 — intervention group
Group type: EXPERIMENTAL
Intervention: Death as an individual end point
Number of subjects: 304
Study 18981486 — intervention group
Group type: EXPERIMENTAL
Intervention: P values for composite outcomes
Number of subjects: 304
Study 18981486 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization as an individual end point
Number of subjects: 304
Study 18981486 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrepancies in individual events
Number of subjects: 304
Study 16935736 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteriostatic normal saline (BNS)
Number of subjects: 221
Study 16935736 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 221
Study 16935736 — intervention group
Group type: COMPARATOR
Intervention: No local anesthesia
Number of subjects: 221
Study 12672713 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with plain water
Number of subjects: 27
Study 12672713 — intervention group
Group type: COMPARATOR
Intervention: Diet without plain water
Number of subjects: 27
Study 10755435 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional brace with early movement
Number of subjects: 60
Study 10755435 — intervention group
Group type: COMPARATOR
Intervention: Below-knee cast
Number of subjects: 60
Study 8884896 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin C 1 g daily
Number of subjects: 12
Study 8884896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1414398 — intervention group
Group type: EXPERIMENTAL
Intervention: s-adenosyl-l-methionine (SAMe)
Number of subjects: 32
Study 1414398 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32
Study 1414398 — intervention group
Group type: EXPERIMENTAL
Intervention: TSH response outside the normal range (7-25 uU/ml)
Number of subjects: 32
Study 1414398 — intervention group
Group type: EXPERIMENTAL
Intervention: absolute deviations from the mean TSH response (16 uU/ml)
Number of subjects: 32
Study 2998975 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti CMV IgG prophylaxis
Number of subjects: 0
Study 2998975 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30045749 — intervention group
Group type: EXPERIMENTAL
Intervention: New participant-driven web application
Number of subjects: 200
Study 30045749 — intervention group
Group type: COMPARATOR
Intervention: Standard reference website
Number of subjects: 200
Study 28836009 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 34
Study 28836009 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia + Paravertebral Block (GA + PVB)
Number of subjects: 34
Study 26295868 — intervention group
Group type: EXPERIMENTAL
Intervention: tucotuzumab/cyclophosphamide (n=64)
Number of subjects: 108
Study 26295868 — intervention group
Group type: COMPARATOR
Intervention: best supportive care (BSC) (n=44)
Number of subjects: 108
Study 26295868 — intervention group
Group type: EXPERIMENTAL
Intervention: tucotuzumab/cyclophosphamide (n=26 with previous PCI)
Number of subjects: 108
Study 26295868 — intervention group
Group type: COMPARATOR
Intervention: best supportive care (BSC) (n=26 with previous PCI)
Number of subjects: 108
Study 26295868 — intervention group
Group type: EXPERIMENTAL
Intervention: tucotuzumab/cyclophosphamide
Number of subjects: 108
Study 26295868 — intervention group
Group type: COMPARATOR
Intervention: best supportive care (BSC)
Number of subjects: 108
Study 23361950 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI score low-risk (0-2)
Number of subjects: 587
Study 23361950 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI score intermediate-risk (3-4)
Number of subjects: 587
Study 23361950 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI score high-risk (5-7)
Number of subjects: 587
Study 22003170 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle-specific intervention (MUSSEL trial)
Number of subjects: 0
Study 22003170 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional activity-based intervention (STOMPS trial)
Number of subjects: 0
Study 22003170 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional activity-based intervention (STEPS trial)
Number of subjects: 0
Study 22003170 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional activity-based intervention (PEDALS trial)
Number of subjects: 0
Study 22003170 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional activity-based intervention (STOMPS, STEPS, PEDALS trials)
Number of subjects: 0
Study 22003170 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional activity-based intervention (STEPS, PEDALS trials)
Number of subjects: 0
Study 19074946 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication surgery
Number of subjects: 357
Study 19074946 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 357
Study 16569544 — intervention group
Group type: EXPERIMENTAL
Intervention: TeleWatch (TW) monitoring
Number of subjects: 49
Study 16569544 — intervention group
Group type: COMPARATOR
Intervention: Clinic-only (CO) carvedilol titration
Number of subjects: 49
Study 14725520 — intervention group
Group type: EXPERIMENTAL
Intervention: Williams Airway Intubator
Number of subjects: 60
Study 14725520 — intervention group
Group type: COMPARATOR
Intervention: Ovassapian Fibreoptic Intubating Airway
Number of subjects: 60
Study 14725520 — intervention group
Group type: COMPARATOR
Intervention: Both airways
Number of subjects: 60
Study 11685160 — intervention group
Group type: EXPERIMENTAL
Intervention: Noetic therapy (stress relaxation, imagery, touch therapy, prayer)
Number of subjects: 150
Study 11685160 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-site prayer
Number of subjects: 150
Study 11685160 — intervention group
Group type: EXPERIMENTAL
Intervention: Noetic therapies
Number of subjects: 150
Study 11685160 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 150
Study 9450158 — intervention group
Group type: EXPERIMENTAL
Intervention: pivagabine (1800 mg orally for 30 days)
Number of subjects: 60
Study 8156066 — intervention group
Group type: EXPERIMENTAL
Intervention: DonJoy Ankle Ligament Protector (ALP)
Number of subjects: 16
Study 8156066 — intervention group
Group type: EXPERIMENTAL
Intervention: Aircast Sport-Stirrup (AS)
Number of subjects: 16
Study 3376901 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (400 micrograms.kg‐1.d‐1 of intravenous Zn)
Number of subjects: 24
Study 3376901 — intervention group
Group type: COMPARATOR
Intervention: No zinc supplementation (control group)
Number of subjects: 24
Study 30075481 — intervention group
Group type: EXPERIMENTAL
Intervention: Practical nutrition lessons
Number of subjects: 166
Study 30075481 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 166
Study 29183701 — intervention group
Group type: EXPERIMENTAL
Intervention: Snack positioned far (70 cm)
Number of subjects: 405
Study 29183701 — intervention group
Group type: COMPARATOR
Intervention: Snack positioned near (20 cm)
Number of subjects: 405
Study 29183701 — intervention group
Group type: EXPERIMENTAL
Intervention: Snack positioned far (70 cm) after removing non-adherers
Number of subjects: 405
Study 29183701 — intervention group
Group type: COMPARATOR
Intervention: Snack positioned near (20 cm) after removing non-adherers
Number of subjects: 405
Study 29183701 — intervention group
Group type: EXPERIMENTAL
Intervention: Snack positioned far (70 cm) in Study 2 after removing non-adherers
Number of subjects: 405
Study 29183701 — intervention group
Group type: COMPARATOR
Intervention: Snack positioned near (20 cm) in Study 2 after removing non-adherers
Number of subjects: 405
Study 27372560 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous mitral valve repair (catheter-based clip implantation)
Number of subjects: 46
Study 24404797 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids (OC)
Number of subjects: 70
Study 24404797 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 70
Study 22951317 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline 1000mg (test preparation)
Number of subjects: 12
Study 22951317 — intervention group
Group type: COMPARATOR
Intervention: Citicoline 1000mg (reference control release tablet)
Number of subjects: 12
Study 21110257 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition Assistance Program (TAP)
Number of subjects: 122
Study 21110257 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 122
Study 18039433 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (prolonged-release form)
Number of subjects: 0
Study 18039433 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 0
Study 16462818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 16462818 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg Orlistat three times a day
Number of subjects: 28
Study 16462818 — intervention group
Group type: COMPARATOR
Intervention: Diet (energy- and fat-restricted)
Number of subjects: 28
Study 16462818 — intervention group
Group type: COMPARATOR
Intervention: Diet continuation for 1 year
Number of subjects: 28
Study 12478093 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (12 patients, treated for a minimum of 6 weeks before surgery)
Number of subjects: 24
Study 12478093 — intervention group
Group type: COMPARATOR
Intervention: Control (12 patients, not treated with finasteride)
Number of subjects: 24
Study 10735889 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine treatment (n = 250)
Number of subjects: 362
Study 10735889 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (n = 112)
Number of subjects: 362
Study 10735889 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 362
Study 10735889 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine treatment
Number of subjects: 362
Study 10735889 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodal status, estrogen receptor (ER) status, tumor size
Number of subjects: 362
Study 8774551 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 methylprednisolone (6MP) i.v. for 3 days at 5 mg/kg/d and for an additional 3 days at 2.5 mg/kg/d followed by po prednisone (1 mg/kg/d)
Number of subjects: 22
Study 8774551 — intervention group
Group type: COMPARATOR
Intervention: po prednisone (1 mg/kg/d)
Number of subjects: 22
Study 1635824 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory flow-resistive load training (75 cm H2O.L-1.s in week 1 and 90 cm H2O.L-1.s in week 2)
Number of subjects: 22
Study 1635824 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory flow-resistive load training
Number of subjects: 22
Study 1635824 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 22
Study 6708393 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac glycosides only (group II)
Number of subjects: 143
Study 6708393 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis and diuretics (group III)
Number of subjects: 143
Study 6708393 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis and K+-saving diuretics (group IV)
Number of subjects: 143
Study 6708393 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis and K+-losing diuretics (group V)
Number of subjects: 143
Study 6708393 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis and furosemide (chronic hypokalemia, group VI)
Number of subjects: 143
Study 6708393 — intervention group
Group type: COMPARATOR
Intervention: Control (group I)
Number of subjects: 143
Study 6708393 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (control group)
Number of subjects: 143
Study 31490414 — intervention group
Group type: EXPERIMENTAL
Intervention: UEScope videolaryngoscope
Number of subjects: 0
Study 31490414 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 0
Study 30094725 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 50
Study 30094725 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 50
Study 26228276 — intervention group
Group type: EXPERIMENTAL
Intervention: PMEA-coated circuits
Number of subjects: 14
Study 26228276 — intervention group
Group type: COMPARATOR
Intervention: Heparin-coated circuits
Number of subjects: 14
Study 25012934 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks (2q4)
Number of subjects: 872
Study 25012934 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 8 weeks after 5 initial monthly doses (2q8)
Number of subjects: 872
Study 25012934 — intervention group
Group type: COMPARATOR
Intervention: Macular laser photocoagulation
Number of subjects: 872
Study 22528165 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg (Group AA)
Number of subjects: 60
Study 22528165 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin on the day of surgery and for seven days post surgery (Group PA)
Number of subjects: 60
Study 22528165 — intervention group
Group type: COMPARATOR
Intervention: Placebo at all times (Group PP)
Number of subjects: 60
Study 19882194 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel (HS)
Number of subjects: 140
Study 19882194 — intervention group
Group type: COMPARATOR
Intervention: Traditional method (TM)
Number of subjects: 140
Study 18482525 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (intravenous insulin with target glycemia levels of 80-110 mg/dl)
Number of subjects: 28
Study 18482525 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy (subcutaneous insulin only when glycemia was 160 mg/dl)
Number of subjects: 28
Study 18482525 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 28
Study 18482525 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 28
Study 18482525 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test after 4 weeks
Number of subjects: 28
Study 15683372 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg) followed by misoprostol (0.8 mg)
Number of subjects: 34
Study 15683372 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg)
Number of subjects: 34
Study 12789384 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg initially, increased to 100 mg or decreased to 25 mg depending on efficacy and tolerance)
Number of subjects: 133
Study 12789384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 12789384 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 133
Study 10534249 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral thalamic stimulation
Number of subjects: 9
Study 8706436 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu380A
Number of subjects: 874
Study 8706436 — intervention group
Group type: COMPARATOR
Intervention: Cu-Fix
Number of subjects: 874
Study 1810359 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg for 1 week, then 300 mg)
Number of subjects: 59
Study 1810359 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin (60 mg for 1 week, then 180 mg)
Number of subjects: 59
Study 3890918 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate ointment
Number of subjects: 0
Study 3890918 — intervention group
Group type: COMPARATOR
Intervention: Ointment base (control)
Number of subjects: 0
Study 30799538 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic surgery
Number of subjects: 82
Study 30799538 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 82
Study 29426288 — intervention group
Group type: EXPERIMENTAL
Intervention: Care management including continuous contact between care manager and patient, a structured management plan, and behavioral activation, around 6-7 contacts over 12 weeks.
Number of subjects: 192
Study 26807956 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-assisted activities (AAA) with a dog, 30-min sessions twice weekly for 12 weeks
Number of subjects: 58
Study 26807956 — intervention group
Group type: COMPARATOR
Intervention: Control group with treatment as usual
Number of subjects: 58
Study 25108482 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning to Cope with Triggers (LCT)
Number of subjects: 127
Study 25108482 — intervention group
Group type: COMPARATOR
Intervention: Avoidance
Number of subjects: 127
Study 25108482 — intervention group
Group type: COMPARATOR
Intervention: Avoidance combined with cognitive behavior therapy (Avoid + CBT)
Number of subjects: 127
Study 25108482 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list (Waitlist)
Number of subjects: 127
Study 21960369 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-bonded dialyzer (PSVE)
Number of subjects: 16
Study 21960369 — intervention group
Group type: COMPARATOR
Intervention: Polyethersulfone membrane (polysulfone)
Number of subjects: 16
Study 19838130 — intervention group
Group type: EXPERIMENTAL
Intervention: vicriviroc (5, 10, or 15 mg/day)
Number of subjects: 28
Study 19838130 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study 23021156 — intervention group
Group type: EXPERIMENTAL
Intervention: P3P intervention
Number of subjects: 448
Study 23021156 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard education plus links to reputable websites)
Number of subjects: 448
Study 16284465 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrin sulphate (DS) gel twice daily
Number of subjects: 109
Study 16284465 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel twice daily
Number of subjects: 109
Study 16284465 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrin sulphate (DS) gel pre-sex
Number of subjects: 109
Study 16284465 — intervention group
Group type: COMPARATOR
Intervention: Observation only arm
Number of subjects: 109
Study 16284465 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrin sulphate (DS) gel
Number of subjects: 109
Study 12365857 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg orally twice daily (n=19)
Number of subjects: 59
Study 12365857 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg orally thrice daily (n=20)
Number of subjects: 59
Study 12365857 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 59
Study 12365857 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline and Cilostazol (both)
Number of subjects: 59
Study 9798811 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus-based local asthma guidelines using a modified Delphi approach
Number of subjects: 42
Study 9798811 — intervention group
Group type: EXPERIMENTAL
Intervention: Local guidelines
Number of subjects: 42
Study 9798811 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education and inhaled steroids usage
Number of subjects: 42
Study 7806712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for depression over 12 weeks
Number of subjects: 115
Study 2791812 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cisapride (8.0 mg)
Number of subjects: 0
Study 2791812 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cisapride (10.0 mg)
Number of subjects: 0
Study 2791812 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cisapride (5.0 mg)
Number of subjects: 0
Study 2791812 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cisapride followed by intravenous atropine
Number of subjects: 0
Study 2791812 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride followed by atropine
Number of subjects: 0
Study 2791812 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine followed by cisapride
Number of subjects: 0